Next generation sequencing (NGS) is a novel procedure for sequencing genomes at low costs and high speed with improved efficiency. The global next generation sequencing market accounted for $3,567 million in 2015, and is anticipated to reach $12,801 million by 2022, registering a CAGR of 19.9% from 2016 to 2022. NGS also known as deep sequencing and parallel sequencing is a technology that has revolutionized molecular biology and genomics research. It is a high throughput, non-Sanger based sequencing method. Next generation sequencing has made sequencing of genomes very rapid and cost-effective. Through this method, billions of DNA strands can be sequenced efficiently. Next generation sequencing has made it possible to conveniently sequence whole genomes, and analyze various DNA-protein interactions. This technique allows the researcher to focus, study, and interpret deep sequence target regions. Next generation sequencing can be utilized through varied interventions such as oncology, biomarker studies, drug discovery, understanding reproductive health, and personalized genomics.

Technological advancements in sequencing platforms, surge in applications of next generation sequencing, and increase in genome mapping programs drives the global next generation sequencing market. In addition, rise in awareness pertaining to next generation sequencing and rise in investment in research, development, and innovation supplement the market growth. However, lack of skilled professionals, ethical & legal limitation related to next generation sequencing, and standardization concerns in sequencing procedures impede the market growth. Furthermore, use of cloud computing as a potential data management service and untapped emerging economies offer lucrative opportunities for the market players.

The next generation sequencing market is segmented based on product, application, technology, end user, and geography. Based on product, the market is segmented into consumables, platforms, and services. The consumables product segment is further classified on the basis of sample preparation consumables and other consumables. The sample preparation consumables are further segmented into DNA fragmentation, end repair, A-Tailing & size selection, library preparation & target enrichment and quality control. The platform NGS product segment is bifurcated into HiSeq, MiSeq, Ion Torrent, SOLiD, Pacbio Rs II & Sequel System, and other sequencing platforms. The services segment is divided into sequencing services and data management. In the NGS product segment, consumables occupied dominant share in 2015, and the segment is expected to maintain this trend during the forecast period. This is attributed to the fact that they are widely used throughout the sample preparation process and other pre-requisite steps of NGS.

Based on application, this market is bifurcated into biomarkers & cancer, diagnostics, reproductive health, personalized medicine, agriculture & animal research, and other applications. The biomarkers & cancer application was the highest revenue contributor in 2015, while the personalized medicine segment is anticipated to grow at the highest rate. The growth for this segment is due to increase in investment in R&D throughout the world along with surge in awareness about NGS applications in precision medicine. Based on technology, the next generation sequencing technology market is classified into sequencing by synthesis, ion semiconductor sequencing, sequencing by ligation, pyrosequencing, single molecule real time sequencing, and other technologies. Sequencing by synthesis technology held the greatest share in 2015 and this trend is estimated to continue throughout the study period as this technology allows both short and long insert paired end reads for high resolution genome sequencing and structural variation detection, sequence assembly & others respectively..

Geographically, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the next generation sequencing market in 2015, and is expected to retain its dominance throughout the forecast period. This is primarily attributed to the higher buying power, availability, and applications that favor the utilization of NGS in this region. There is also an increase in agreements and collaborations between different market players and health centers to promote and utilize NGS in this region. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, owing to the improvement in R&D facilities, available disposable income, and rapidly developing economic conditions.

Product development is the key strategy adopted by market players. The report provides a comprehensive analysis of the key players that operate in the global next generation sequencing market.

KEY PLAYERS PROFILED

Illumina, Inc.
Thermo Fisher Scientific, Inc.
Pacific Biosciences of California, Inc.
Beijing Genomics Institute
Qiagen N.V.
454 Life Sciences Corporation (Roche Holding AG)
Agilent Technologies, Inc.
Perkinelmer, Inc.
Genomatix GmbH
PierianDx.

KEY MARKET BENEFITS

The study provides an in-depth analysis of the global next generation sequencing market along with the current trends and future estimations to elucidate the imminent investment pockets.
The report presents quantitative analysis of the market for the period of 2014-2022 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on product type assists in understanding the trends in the industry.
Key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry

Next generation sequencing Market Key Segments:

By Product

Consumables
Sample Preparation Consumables
DNA Fragmentation, End Repair, A-Tailing and Size Selection
Library Preparation & Target Enrichment
Quality Control
Other Consumables
Platforms
HiSeq
MiSeq
Ion Torrent
SOLiD
Pacbio Rs II and Sequel System
Other Sequencing Platforms
Services
Sequencing Services
RNA Sequencing
Whole Exome Sequencing
Whole Genome Sequencing
Targeted Sequencing
Chip Sequencing
De Novo Sequencing
Methyl Sequencing
Data Management Services
NGS Data Analysis Services
NGS Data Analysis Software & Workbenches
NGS Storage, Management and Cloud Computing Solutions

By Application

Diagnostics
Biomarkers and Cancer
Reproductive Health
Personalized Medicine
Agriculture and Animal Research
Other Applications

By Technology

Sequencing by Synthesis
Ion Semiconductor Sequencing
Sequencing by Ligation
Pyrosequencing
Single Molecule Real Time Sequencing
Other Technologies

By End User

Academic & Government Research Institutes
Pharmaceutical Companies
Biotechnology Companies
Hospitals & Clinics

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Taiwan
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA

Other players in the value chain include (profiles not included in the report)

Eurofins Scientific
Gatc Biotech AG
Macrogen, Inc.
Oxford Nanopore Technologies, Ltd.
Bio-Rad Laboratories, Inc.
DNASTAR, Inc.
Biomatters Ltd.
Partek Inc.
New England Biolabs, Inc.
Myriad Genetics, Inc.